New York University Skip to Content Skip to Search Skip to Navigation Skip to Sub Navigation

NYU Neuroscientists Find Promise in Addressing Fragile X Afflictions

September 19, 2012
15

Neuroscientists at New York University have devised a method that has reduced several afflictions associated with Fragile X syndrome (FXS) in laboratory mice. Their findings, which are reported in the journal Neuron, offer new possibilities for addressing FXS, the leading inherited cause of autism and intellectual disability.

Those afflicted with FXS do not possess the protein FMRP, which is a suppressor of protein synthesis. Absent this suppressor, protein synthesis is exaggerated, producing a range of mental and physical disorders.

Previous research has indirectly targeted protein synthesis by seeking to temper, but not block, this process. The NYU researchers, by contrast, sought a more fundamental intervention—removing the enzyme, p70 ribosomal S6 kinase 1, or S6K1, which has previously been shown to regulate protein synthesis in FXS mice. By addressing this phenomenon at the molecular level, they hoped to diminish many of the conditions associated with FXS.

To determine the impact of this intervention, the researchers compared the behaviors of these FXS mice with those normal mice while also observing the physical attributes of these same FXS mice.

Their results showed that protein synthesis in the FXS mice lacking S6K1 became similar to that of normal mice. Moreover, through a series of experiments and other measurements (e.g., navigating a maze, interacting with other mice), they found both physical and behavioral improvements in the FXS mice:

* The FXS mice missing the S6K1 enzyme showed greater ability than other FXS mice to adjust their behaviors when facing conditions that were similar, but not identical, to previous experiences. This attribute, behavioral flexibility, is typically diminished is those afflicted with FXS. In this experiment, the FXS mice missing the S6K1 enzyme were more successful than other FXS mice to navigate a maze that was similar to a maze they had previously mastered.

* The FXS mice missing the S6K1 enzyme showed enhanced social behaviors, which are measured through a commonly used “social novelty test.” Under this method, mice interact with each other multiple times to gauge familiarity. In this experiment, the FXS mice missing the S6K1 enzyme showed greater familiarity with mice they previously encountered than did other FXS mice. Humans afflicted with FXS have diminished abilities for social interaction.

* The FXS mice missing the S6K1 enzyme showed a correction in three physical traits often associated with this condition: immature dendritic spine morphology, which indicates abnormal connections between neurons, excessive weight gain, and macro-orchidism, or enlarged testicles.

However, the researchers did not find uniform improvements in the tested FXS mice—they still engaged in excessive repetitive behaviors (i.e., repeatedly burying marbles in an experiment), a common trait among those afflicted with FXS.

Nonetheless, the research team said the findings showed remarkable promise.

“We think these results set the stage for a viable pharmacological approach to target S6K1, with the aim of diminishing or even reversing the afflictions associated with Fragile X syndrome,” said Eric Klann, a professor in NYU’s Center for Neural Science and the study’s senior author.

The study’s other co-authors were: Aditi Bhattacharya, Hanoch Kaphzan, Amanda Alvarez-Dieppa, and Jaclyn Murphy of NYU’s Center for Neural Science and Philippe Pierre of Université de la Méditerranée in Marseille, France.

The research was supported by grants from the National Institutes of Health and the FRAXA Research Foundation.

This Press Release is in the following Topics:
Research, Arts and Science, Faculty

Type: Press Release

Press Contact: James Devitt | (212) 998-6808

NYU Neuroscientists Find Promise in Addressing Fragile X Afflictions

NYU neuroscientists have devised a method that has reduced, in laboratory mice, several afflictions associated with Fragile X syndrome (FXS), the leading inherited cause of autism and intellectual disability. ©iStockphoto.com/Fernando Regalado.


Search News



NYU In the News

Entrepreneurship Lab Opens at NYU

Crain’s New York Business covered the opening of the Mark and Debra Leslie Entrepreneurial eLab, which will be the headquarters for NYU’s Entrepreneurial Institute and all of the University’s programs aimed at promoting innovation and startups.

A Globalizer for N.Y.U. in Abu Dhabi

The New York Times profiled Bill Bragin who will become the first executive artistic director of NYU Abu Dhabi’s new performing arts center.

Think Tank to Ponder a Future for Ballet

The New York Times profiled Jennifer Homans, the director of NYU’s new Center for Ballet and the Arts.

The Brilliant Ten: Jonathan Viventi Builds Devices That Decode Thoughts

Popular Science named Assistant Bioengineering Professor Jonathan Viventi as one of its “brilliant ten” for his research into brain implants that could one day halt epileptic episodes:

Living and Leaving the Dream: Adrian Cardenas’ Journey from the Major Leagues to College

The New York Times ran a feature on Adrian Cardenas, a former major league baseball player who is now studying philosophy and creating writing at NYU.

NYU Footer